These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35920297)

  • 1. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
    Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
    Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
    Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
    Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
    Regan MM; Mantia CM; Werner L; Tarhini AA; Larkin J; Stephen Hodi F; Wolchok J; Postow MA; Stwalley B; Moshyk A; Ritchings C; Re S; van Dijck W; McDermott DF; Atkins MB
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
    Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
    JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
    N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
    Long GV; Lipson EJ; Hodi FS; Ascierto PA; Larkin J; Lao C; Grob JJ; Ejzykowicz F; Moshyk A; Garcia-Horton V; Zhou ZY; Xin Y; Palaia J; McDonald L; Keidel S; Salvatore A; Patel D; Sakkal LA; Tawbi H; Schadendorf D
    J Clin Oncol; 2024 Nov; 42(33):3926-3934. PubMed ID: 39137386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
    Long GV; Stephen Hodi F; Lipson EJ; Schadendorf D; Ascierto PA; Matamala L; Salman P; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; Janoski De Menezes J; Dalle S; Arance A; Grob JJ; Keidel S; Shaikh A; Sobiesk AM; Dolfi S; Tawbi HA
    NEJM Evid; 2023 Apr; 2(4):EVIDoa2200239. PubMed ID: 38320023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
    Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
    Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
    Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
    Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis.
    Li X; Wang J; Yao Y; Yang L; Li Z; Yu C; Zhao P; Yu Y; Wang L
    Oncotarget; 2017 Oct; 8(48):83637-83649. PubMed ID: 29137370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.
    Xu Y; Hezam K; Ali MG; Wang Y; Zhang J
    Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):386-394. PubMed ID: 34014122
    [No Abstract]   [Full Text] [Related]  

  • 18. Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens.
    Ossato A; Mengato D; Chiumente M; Messori A; Damuzzo V
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.